|
|
Article: UCB and Jazz Pharmaceuticals Announce Expansion of Xyrem(R) License Agreement to Include Fibromyalgia Syndrome.
- Article from:
- PR Newswire
- Article date:
- October 3, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-- UCB also adds new marketing territories under expanded agreement --
BRUSSELS, Belgium and PALO ALTO, Calif., Oct. 3 /PRNewswire/ -- UCB (Euronext Brussels: UCB) and Jazz Pharmaceuticals, Inc. today announced the signing of an expanded product license agreement for Xyrem(R) (sodium oxybate).
Under the agreement, UCB obtains the right to commercialize Xyrem for the treatment of fibromyalgia syndrome, if and when the product is approved for this indication. On September 7, 2006, Jazz Pharmaceuticals announced the initiation of its Phase III clinical development program evaluating the use of Xyrem for the treatment of fibromyalgia syndrome.
...